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Stem cell side show
B
efore scientists can harness heart stem cells to repair damage to the 
organ, they have to pin down the elusive cells. On page 329, 
  Oyama et al. bolster the case for a group of cells known as side 
population cells, showing for the ﬁ  rst time that they home in on injured heart 
muscle and differentiate into all the types of cardiac cells in vivo.
Previous research has turned up several candidates for cardiac stem 
cells, including the side population cells. In the bone marrow, side population 
cells function as stem cells. The situation in the heart wasn’t clear, however. If 
they are grown with heart muscle cells in vitro, cardiac side population (CSP) 
cells can specialize into heart 
muscle. However, researchers 
didn’t know what stimulates the 
cells to differentiate or what 
they’re capable of in vivo.
Oyama et al. offered cul-
tured CSP cells a variety of 
growth factors, but found that 
only two—including the hor-
mone oxytocin—coaxed the 
cells to differentiate. Whether 
these molecules control differen-
tiation in vivo isn’t clear, the 
scientists say, but their discovery 
might help researchers devise a 
recipe for nurturing the cells.
To study CSP cell behavior 
in vivo, the researchers injected tagged cells into rats. CSP cells ended up in 
several organs, but mainly in the heart. More of them found their way to the 
organ if it was damaged, indicating that they respond to signals from injured 
cardiac tissue. These new arrivals specialized into heart muscle cells, but also 
into blood vessel and connective tissue cells. That ﬁ  nding demonstrates that 
CSP cells can spawn all cell types in the heart, the researchers note. They 
conclude that CSP cells are serving as stem cells in the heart. 
How kinases dodge trouble
N
ewly synthesized kinases have one 
thing in common with teenagers: they 
can go astray without supervision. As 
Mandal et al. reveal on page 319, cells keep 
the regulatory proteins in line by assigning them 
a bodyguard. The molecular guardian helps 
kinases avoid premature destruction.
Researchers already knew that the protective 
protein, Cdc37, teams with the chaperone Hsp90 
to help freshly synthesized kinase chains fold into 
shape. But evidence indicates that Cdc37 also 
works independently of Hsp90. To pin down 
Cdc37’s other job, the researchers measured the 
amounts of 65 kinases in yeast cells that produce 
a defective version of the Cdc37 protein. Levels 
of 80% of the kinases were lower than in control 
cells. However, faulty Cdc37 didn’t alter gene 
expression, and translation appeared to run 
normally, suggesting that the decline occurred 
after cells fashioned the kinases.
They found that, in cells with defective Cdc37, 
newly synthesized kinases broke down swiftly. 
But the kinases escaped destruction if the 
researchers fi   rst added a drug that stalls the 
proteasome, the cellular garbage disposal that 
chops up misshapen proteins. Without protection 
from Cdc37, newly formed kinases appear to 
get shunted into the proteasome for recycling. 
Cdc37 latches onto its targets at their active site 
during or shortly after translation. The researchers 
suspect that the protein can somehow sense its 
charges’ shape and prevent them from misfolding, 
which would trigger their demolition. 
Liberating TGF𝗃
O
veractive TGFβ spurs Marfan’s syndrome, which might have 
been responsible for Abraham Lincoln’s rangy physique. But 
how the molecule gets released from storage and switched on 
is uncertain. On page 355 Chaudhry et al. ﬁ  ll in a key step, showing 
that a piece of an extracellular matrix (ECM) protein frees inert TGFβ.
TGFβ helps control whether cells move, divide, specialize, and survive. Cells often lock up the potent 
cytokine by fastening a complex containing its inactive form to ﬁ  brillin-1 ﬁ  bers in the ECM. Discovering how 
this sequestered TGFβ breaks loose might clarify the mechanism of Marfan’s syndrome, in which ﬁ  brillin-1 
mutations lead to symptoms such as a weakened aorta and leaky heart valves.
Chaudhry et al. demonstrated that ﬁ   brillin-1 itself helps release the TGFβ complex. The researchers 
narrowed this ability to a small fragment of the protein. The segment doesn’t bind to TGFβ. Instead, it attaches 
tightly to the end of ﬁ  brillin-1 that carries the cytokine complex. The researchers hypothesize that this interaction 
alters the shape of full-length ﬁ  brillin-1 and dislodges the inert TGFβ. Other enzymes could then activate it. 
Fibrillin fragments wouldn’t normally be loose in the extracellular matrix, but some ﬁ  brillin mutations 
distort the protein so that it is more likely to be sliced up by ECM enzymes. That might unleash the TGFβ-
releasing segment, the researchers speculate. 
Only particular ﬁ  brillin-1 fragments activate TGF𝗃 signaling.
A CSP-derived cell (green) settles into injured 
heart tissue.